This issue explores significant developments in transplantation. Our expert reviews this month include five papers from the various working groups at the Global Transplant Summit in Santander addressing sufficiency, transparency, and oversight for equity in transplantation. New international expert lead guidelines on the management of the BK virus are also included. Elsewhere the issue addresses the impact of mitral annular calcification (MAC) on liver transplant outcomes, studies on living donor liver transplantation (LDLT) and the complexities of donor-specific antibodies (DSAs) and ABO incompatibility, the efficacy of nucleos(t)ide analogs in preventing hepatitis B virus (HBV) recurrence post-liver transplantation. Furthermore, it addresses the evolving role of donor-derived cell-free DNA (dd-cfDNA) as an early biomarker for renal allograft rejection, demonstrating its potential to facilitate timely intervention and improve patient outcomes compared to traditional markers like serum creatinine. These studies collectively advance our understanding and clinical approach to transplantation, offering insights that may redefine current practices and improve patient care worldwide.